Systemic treatments for women with breast cancer: outcome with relation to screening for the disease

被引:20
作者
Goldhirsch, A
Colleoni, M
Domenighetti, G
Gelber, RD
机构
[1] European Inst Oncol, Dept Med, Int Breast Canc Study Grp, I-20141 Milan, Italy
[2] Osped Reg Lugano Civ, Oncol Inst So Switzerland, Lugano, Switzerland
[3] Cantonal Hlth Off Canton Ticino, Bellinzona, Switzerland
[4] Univ Lausanne, Inst Hlth Econ & Management, CH-1015 Lausanne, Switzerland
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
adjuvant treatments; breast cancer; screening;
D O I
10.1093/annonc/mdg327
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Early detection and proper care of breast cancer are currently the best available approaches to the treatment of patients with the disease. In countries with a breast cancer screening programme, there has been a demonstrated reduction in breast cancer-related mortality. Such reduction has also been observed in Switzerland, a country in which no national programme of screening is available. Although there is no doubt that early diagnosis might have had a major role in reducing breast cancer mortality the magnitude of this effect is unknown. Research with tailored approaches on alternative imaging for early detection of breast cancer in high-risk women and on treatments offered according to proper criteria of responsiveness to therapies is warranted.
引用
收藏
页码:1212 / 1214
页数:3
相关论文
共 18 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]  
[Anonymous], 1996, Lancet, V348, P1189
[3]  
[Anonymous], 1986, J Clin Oncol, V4, P186
[4]  
[Anonymous], 1988, NEW ENGL J MED, V319, P1681
[5]  
CALMONTE R, 2000, ENQUETE SUISSE SANTE
[6]   RANDOMIZED TRIAL OF 3 DIFFERENT REGIMENS OF COMBINATION CHEMOTHERAPY IN PATIENTS RECEIVING SIMULTANEOUSLY A HORMONAL TREATMENT FOR ADVANCED BREAST-CANCER [J].
CAVALLI, F ;
PEDRAZZINI, A ;
MARTZ, G ;
JUNGI, WF ;
BRUNNER, KW ;
GOLDHIRSCH, A ;
MERMILLOD, B ;
ALBERTO, P .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (11) :1615-1624
[7]  
Clarke M, 1998, LANCET, V351, P1451
[8]  
Goldhirsch A, 2001, J Natl Cancer Inst Monogr, P44
[9]  
HAKAMA M, 1995, LANCET, V345, P221
[10]  
Kelley S, 2000, Brief Bioinform, V1, P131, DOI 10.1093/bib/1.2.131